Activation of mTOR signaling pathway contributes to survival of cervical cancer cells

Gynecologic Oncology

Volumn 117, Issue 1, 2010, Pages 103-108

  Ji, Jing ^a   Zheng, Peng Sheng ^a,b  

^a First Affiliated Hospital   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Cervical cancer; mTOR; P70S6K; Rapamycin; siRNA

Indexed keywords

CISPLATIN; DNA; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA CONTENT; DNA FLANKING REGION; DOWN REGULATION; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE SILENCING; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UTERINE CERVIX CANCER; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; CISPLATIN; DOWN-REGULATION; FEMALE; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; UTERINE CERVICAL NEOPLASMS;

EID: 77949281423     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.12.020     Document Type: Article

References (13)

1. Paavonen J. Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. Int. J. Infect. Dis. 11 Suppl 2 (2007) S3-S9
2. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18 (2004) 1926-1945
3. Faivre S., Kroemer G., and Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug. Discov. 5 (2006) 671-688
4. Zhang Y.J., Dai Q., Sun D.F., et al. mTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer. Ann. Surg. Oncol. 16 (2009) 2617-2628
5. Marinov M., Ziogas A., Pardo O.E., et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin. Cancer Res. 15 (2009) 1277-1287
6. Hou G., Xue L., Lu Z., Fan T., Tian F., and Xue Y. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett. 253 (2007) 236-248
7. Raymond E., Alexandre J., Faivre S., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22 (2004) 2336-2347
8. Rizzieri D.A., Feldman E., Dipersio J.F., et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 14 (2008) 2756-2762
9. Amato R.J., Jac J., Giessinger S., Saxena S., and Willis J.P. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 115 (2009) 2438-2446
10. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
11. Pyronnet S., and Sonenberg N. Cell-cycle-dependent translational control. Curr. Opin. Genet. Dev. 11 (2001) 13-18
12. Harada H., Andersen J.S., Mann M., Terada N., and Korsmeyer S.J. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9666-9670
13. Findlay G.M., Harrington L.S., and Lamb R.F. TSC1-2 tumour suppressor and regulation of mTOR signalling: linking cell growth and proliferation. Curr. Opin. Genet. Dev. 15 (2005) 69-76